Holen Sie sich die Stockscreener-App
10.05
0.16%
0.0156
Schlusskurs vom Vortag:
$10.03
Offen:
$10.04
24-Stunden-Volumen:
800
Relative Volume:
0.01
Marktkapitalisierung:
$336.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.11%
1M Leistung:
+0.26%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$10.03
$10.05
1-Wochen-Bereich:
$10.03
$10.05
52-Wochen-Spanne:
$9.96
$10.27
Drugs Made In America Acquisition Corp Stock (DMAA) Company Profile
Firmenname
Drugs Made In America Acquisition Corp
Sektor
Branche
Telefon
954-870-3104
Adresse
2 PELICAN DR., FORT LAUDERDALE
Vergleichen Sie DMAA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DMAA
Drugs Made In America Acquisition Corp
|
10.05 | 336.18M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
6.63 | 1.80B | 3.13B | 50.80M | 555.00M | 0.1772 |
|
AACT
Ares Acquisition Corporation Ii
|
11.20 | 697.50M | 0 | 16.92M | -1.35M | 0.29 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.67 | 460.58M | 0 | 1.30M | 0 | 0.0301 |
|
AAM
Aa Mission Acquisition Corp
|
10.27 | 451.61M | 0 | 0 | 0 | 0.00 |
|
EQV
Eqv Ventures Acquisition Corp
|
10.09 | 450.63M | 0 | 0 | 0 | 0.00 |
Drugs Made In America Acquisition Corp Aktie (DMAA) Neueste Nachrichten
WEBTOON Entertainment Inc. (NASDAQ:WBTN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Q1 2025 SPAC Market Update & Outlook - Business Wire
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
Pfizer Inc. - Britannica
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
Theratechnologies’ stock soars on disclosure of acquisition offer by U.S. company - Montreal Gazette
'I bought their dream': How a US company's huge land deal in Senegal went bust - Yahoo
Drugs Made In America Acquisition Corp. (DMAA) reports earnings - qz.com
Bright Green Unveils Massive $2B Cannabis Strategy with Zero Shareholder Dilution - StockTitan
Bright Green Corporation Announces the next steps for the completion of its restructuring plan - The Manila Times
DRUGS MADE IN AMERICA ACQUISITION CORP- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
India-based Syngene acquires its first US biologics site - Manufacturing Dive
7 Best Weight Loss Drug Stocks to Buy in 2025 | Investing | U.S. News - U.S News & World Report Money
Brokerages Set TWFG, Inc. (NASDAQ:TWFG) Target Price at $31.86 - Defense World
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines - Business Wire
Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion | Eli Lilly and Company - Eli Lilly and Company
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine - CNN
Drugs Made in America Acquisition Corp. Forms Advisory Team to Pursue Pharmaceutical Business Acquisitions - Nasdaq
Popular cannabis brand declares Chapter 11 bankruptcy - TheStreet
NewGen Issues Clarification on Press Release Titled 'NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director” dated February 20, 2025 - The Manila Times
Drugs Made In America Acquisition Corp. Announces Trading Options for Public Offering Units Starting February 25, 2025 - Nasdaq
Mink Ventures Completes Acquisition of Warren Ni, Cu, Co Patents - The Manila Times
Drugs Made In America Acquisition Corp. Announces Closing of Full Exercise of IPO Over-Allotment Option - TradingView
Drugs Made In America Acquisition Corp. Secures Additional $30 Million in IPO as Underwriter Fully Exercises Overallotment Option - Nasdaq
U.S. investors, Big Pharma race to find new medicines in China - CNBC
Drugs Made In America Acquisition Corp.’s $200 Million Initial Public Offering - Global Legal Chronicle
Trump wants to put tariffs on prescription drugs. Experts warn it could backfire. - Yahoo Finance
Bain throws down $3.3B to acquire Japan's Mitsubishi Tanabe Pharma - Fierce Pharma
United Parcel Service (UPS) | History, Services, & Facts - Britannica
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs - Seeking Alpha
IPO NewsUS IPO Weekly Recap: Active January closes out with several sizable IPOs - renaissancecapital.com
Drugs Made In America Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering - The Manila Times
Drugs Made In America Acquisition Prices $200 Million IPO - MarketScreener
Drugs Made in America Acquisition Corp. (DMAAU) Prices $200M IPO - SPAC Insider
Bright Green Corporation Has Signed Agreement with Majority - GlobeNewswire
How UnitedHealth and Rivals Made $7.3 Billion Marking Up Drugs: FTC - Newsweek
How a Company Makes Millions Off a Hospital Program Meant to Help the Poor - The New York Times
How Trump’s Greenland demands could impact Ozempic costs - The Hill
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc. - Johnson & Johnson
The top 10 biopharma M&A deals of 2024 - Fierce Pharma
What Trump’s Denmark Tariff Threat Means for Ozempic Drugmaker Novo Nordisk - Barron's
Analysts Set Elevation Oncology, Inc. (NASDAQ:ELEV) Price Target at $7.20 - Defense World
2024 drug approvals: Small companies loom large with several key FDA nods - Fierce Pharma
Layoffs Continued Across Biopharma in 2024 - BioSpace
Bright Green enters into restructuring security agreement with Lynn Stockwell - Yahoo Finance
Bright Green (BGXX) Announces Major Restructuring: Founder Returns as CEO, Plans API Manufacturing Focus - Stock Titan
Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval - Reuters
Dallas Entrepreneur Seeks to Build Nationwide Compounding Pharmacy Network - Dallas Innovates
7 Companies Owned by Pfizer - Investopedia
Top 10 Asthma Drug Companies | Provides Best Medicines - Market.us Media
FTC’s watchdog role in pharma mergers: Road bumps and the way forward - Norton Rose Fulbright
Finanzdaten der Drugs Made In America Acquisition Corp-Aktie (DMAA)
Es liegen keine Finanzdaten für Drugs Made In America Acquisition Corp (DMAA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.40%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):